viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics R&D research to be published in leading veterinary journal

The company will present findings of study into cannabinoid treatment for companion animals at AVA Innovation Symposium next month.

Dog and cat
The company is focused on medicinal cannabis treatments for dogs and cats

CannPal Animal Therapeutics Ltd (ASX:CP1) is being recognised for its robust and leading research into medicinal cannabis treatments for animals through participation in Australia’s largest veterinary conference and publication of its first research abstract.

This will provide the company the opportunity to directly present to 1,400 veterinarians at the Australian Veterinary Association (AVA) Innovation, Research and Development Symposium in May.

CannPal will also reach more than 5,000 through publication of its abstract in the Australian Veterinary Journal (AVJ), which is Australia’s premier veterinary scientific journal.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

Founder and managing director Layton Mills said the presentation and AVJ publication was a significant milestone for the company.

He said: “There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.

“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines”.

“Building a trusting relationship” with vets

“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”

During the AVA Innovation Symposium in Perth next month CannPal’s head of R&D Dr Margaret Curtis will present on the company’s Phase 1 trial results.

This will include the pharmacokinetic, safety, gene expression and inflammatory biomarker results from the robust randomised three group parallel pharmacokinetic study completed in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The AVA event between May 5 and 10 is the largest veterinary conference in Australia, with an average of 1,400 veterinary professionals expected to attend.

It is a platform for industry and animal researchers to present their clinical research and findings directly to the veterinary profession.

The Innovation Symposium will be on Sunday, May 5, and Dr Curtis will present at 3.35pm alongside speakers from world-leading animal health companies such as Bayer, Ceva and Virbac.

Abstracts from the symposium will be published in the AVJ, which is Australia’s premier veterinary scientific journal, reaching an audience of over 5,000 AVA members.

CannPal generates “exciting results”

Dr Curtis said: “This is a great opportunity to get our initial results out into the veterinary fraternity in Australia.

“The AVJ is widely read, and publication of this work will further disseminate the exciting results that CannPal is generating, bringing us closer to potentially approvable cannabis-derived medicines for pets.”

MD Mills said: “Since founding the company, CannPal has placed diligent focus on building a credible and experienced R&D team to complete robust and world leading research on the safety and efficacy of cannabis-derived compounds for companion animals.

“The AVA Symposium is an opportunity for CannPal to start sharing some of that research with the scientific and veterinary community, in the hopes of establishing CannPal as a clear leader in this field.”

READ: CannPal Animal Therapeutics director buys 100,000 shares on-market

CannPal is researching and developing medicines derived from cannabinoids with the aim of providing veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.08 AUD

Market: ASX
Market Cap: $7.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...



CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

3 min read